Literature DB >> 17926018

[Coagulopathy resulting from lupus anticoagulant antibodies as a paraneoplastic phenomenon in renal cell carcinoma relapse].

N Berdjis1, M Meier, F Hoeppner, H Behrendt.   

Abstract

Lupus anticoagulant syndrome (LAS) is a form of coagulopathy with protracted PTT and an elevated risk of thromboembolic events, which occasionally occurs as a paraneoplastic phenomen in the presence of tumors. It is diagnosed by specific coagulation tests that identify lupus anticoagulant antibodies. We present the case of a 57-year-old woman with a coagulopathy caused by lupus anticoagulant antibodies as a paraneoplastic phenomenon in the course of a relapse of clear cell renal cell carcinoma in the area of the ipsilateral adrenal gland 18 months after tumor nephrectomy. After adrenalectomy with concomitant administration of low-molecular-weight heparin the PTT became normal and the diagnostic tests for lupus anticoagulant antibodies became negative.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17926018     DOI: 10.1007/s00120-007-1557-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  16 in total

1.  Lupus type anticoagulant in a patient with renal cell carcinoma: an autoimmune paraneoplastic syndrome.

Authors:  M Hammad Ather; Shoaib Mithani; Saquib Bhutto; Salman Adil
Journal:  J Urol       Date:  2002-05       Impact factor: 7.450

Review 2.  Laboratory diagnosis and management challenges in the antiphospholipid syndrome.

Authors:  M L Bertolaccini; M A Khamashta
Journal:  Lupus       Date:  2006       Impact factor: 2.911

Review 3.  The antiphospholipid syndrome: an update.

Authors:  Massimo Franchini
Journal:  Clin Lab       Date:  2006       Impact factor: 1.138

4.  Thrombotic manifestations of the antiphospholipid syndrome in patients with malignancies.

Authors:  Wolfgang Miesbach; Inge Scharrer; Ronald Asherson
Journal:  Clin Rheumatol       Date:  2006-01-25       Impact factor: 2.980

5.  Recurrent stent thrombosis associated with lupus anticoagulant due to renal cell carcinoma.

Authors:  D F Muir; A Stevens; R O Napier-Hemy; F Fath-Ordoubadi; N Curzen
Journal:  Int J Cardiovasc Intervent       Date:  2003

6.  Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome.

Authors:  M J Cuadrado; P Buendía; F Velasco; M A Aguirre; N Barbarroja; L A Torres; M Khamashta; C López-Pedrera
Journal:  J Thromb Haemost       Date:  2006-09-12       Impact factor: 5.824

Review 7.  Molecular pathogenesis of the antiphospholipid syndrome.

Authors:  Jacob H Rand
Journal:  Circ Res       Date:  2002-01-11       Impact factor: 17.367

8.  Incidence of adrenal involvement and assessing adrenal function in patients with renal cell carcinoma: is ipsilateral adrenalectomy indispensable during radical nephrectomy?

Authors:  Hiroshi Yokoyama; Masatoshi Tanaka
Journal:  BJU Int       Date:  2005-03       Impact factor: 5.588

9.  Pulmonary embolism and lupus anticoagulant in a woman with renal cell carcinoma.

Authors:  A Papagiannis; A Cooper; J Banks
Journal:  J Urol       Date:  1994-09       Impact factor: 7.450

10.  Antiphospholipid antibodies and venous thromboembolism.

Authors:  J S Ginsberg; P S Wells; P Brill-Edwards; D Donovan; K Moffatt; M Johnston; P Stevens; J Hirsh
Journal:  Blood       Date:  1995-11-15       Impact factor: 22.113

View more
  1 in total

1.  Hypernephroma presenting with cutaneous leukocytoclastic vasculitis and lupus anticoagulant: resolution after nephrectomy.

Authors:  Nigel P Murray; Amparo Ruíz; Eduardo Reyes
Journal:  Case Rep Urol       Date:  2012-08-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.